Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 106-133 , May 2010

Colon cancer

  • Roberto Labianca

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 035 269860.
    • ,
  • Giordano D. Beretta

      Affiliations

    • Ospedale Sant’Orsola Fatebenefratelli, Brescia, Italy
    • ,
  • Basem Kildani

      Affiliations

    • Ospedale Sant’Orsola Fatebenefratelli, Brescia, Italy
    • ,
  • Laura Milesi

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • ,
  • Federica Merlin

      Affiliations

    • Ospedale Sant’Orsola Fatebenefratelli, Brescia, Italy
    • ,
  • Stefania Mosconi

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • ,
  • M. Adelaide Pessi

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • ,
  • Tiziana Prochilo

      Affiliations

    • Ospedale Sant’Orsola Fatebenefratelli, Brescia, Italy
    • ,
  • Antonello Quadri

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • ,
  • Gemma Gatta

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
    • ,
  • Filippo de Braud

      Affiliations

    • START Project and European Institute of Oncology, Milan, Italy
    • ,
  • Jacques Wils

      Affiliations

    • Laurentius Hospital, Roermond, The Netherlands

,Accepted 6 January 2010.

References 

  1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer. Vol. VIII. IARC Scient. Publ. No. 155. 2002.
  2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon: IARC Press; 2004.
  3. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(Suppl. 8):S4–S66
  4. Grande E, Inghelmann R, Francisci S, et al. Regional estimates of colorectal cancer burden in Italy. Tumori. 2007;93:352–359
  5. Berrino F, De AR, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: results of the EUROCARE-4 study. Lancet Oncol. 2007;8:773–783
  6. Coleman MP, Gatta G, Verdecchia A, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol. 2003;14(Suppl. 5):v128–v149
  7. Engholm G, Kejs AM, Brewster DH, et al. Colorectal cancer survival in the Nordic countries and the United Kingdom: excess mortality risk analysis of 5 year relative period survival in the period 1999 to 2000. Int J Cancer. 2007;121:1115–1122
  8. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000–2002 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–796
  9. Kwak EL, Chung DC. Hereditary colorectal cancer syndromes: an overview. Clin Colorectal Cancer. 2007;6:340–344
  10. Tomatis L. Cancer, causes, occurrence and control. Lyon: IARC Press. Pubbl. no. 100; 1990.
  11. WCRF& AICR. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
  12. In:  Stewart BW,  Kleihus P editor. World cancer report. Lyon: IARC Press; 2003;
  13. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:725–731
  14. Asano TK, McLeod RS. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum. 2004;47:665–673
  15. von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007;50:839–855
  16. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535
  17. Cali RL, Pitsch RM, Thorson AG, et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum. 1993;36:388–393
  18. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28–36
  19. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991–1004
  20. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214–218
  21. Cochrane. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001216 Screening for colorectal cancer using the faecal occult blood test, Hemoccult; 2007.
  22. Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: evidence and practice in Europe 2008. Eur J Cancer. 2008;44:1404–1413
  23. Advisory Committee on Cancer Prevention (ACCP) . Recommendations on cancer screening in the European union. Eur J Cancer. 2000;36:1473–1478
  24. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124:544–560
  25. Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature. 1987;328:614–616
  26. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532
  27. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298–303
  28. Kinzler KW, Nilbert MC, Vogelstein B, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science. 1991;251:1366–1370
  29. Broders AC. The grading of carcinoma. Minn Med. 1925;8:726–730
  30. Dukes CE. The classification of cancer of the rectum. J Pathol. 1932;35:323–332
  31. Qizilbash AH. Pathologic studies in colorectal cancer. A guide to the surgical pathology examination of colorectal specimens and review of features of prognostic significance. Pathol Annu. 1982;17:1–46
  32. Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology. 1986;10:437–459
  33. Vining DJ, Gelfand DW, Bechtold RE. Technical feasibility of colon imaging with helical CT and virtual reality. AJR Am J Roentgenol. 1994;162(Suppl.):104
  34. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med. 2003;349:2191–2200
  35. Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA. 2004;291:1713–1719
  36. Luboldt W, Bauerfeind P, Wildermuth S, et al. Colonic masses: detection with MR colonography. Radiology. 2000;216:383–388
  37. Hartmann D, Bassler B, Schilling D, et al. Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy. Radiology. 2006;238:143–149
  38. Leung WK, Lam WW, Wu JC, et al. Magnetic resonance colonography in the detection of colonic neoplasm in high-risk and average-risk individuals. Am J Gastroenterol. 2004;99:102–108
  39. Bresalier RA, Boland CR, Itzkowitz SH, Kim YS. Basic gastrointestinal oncology. In:  Kern F,  Blum AL editor. The gastroeneterology annual. vol. 2:Amsterdam: Elsevier/North Holland; 1989;p. 271–319
  40. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1986;104:66–73
  41. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In:  De Vita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles and practice of oncology. 4th ed.. Philadelphia: JB Lippincott Company; 1993;p. 929–977
  42. Eisenberg B, DeCosse JJ, Harford F, Michalek J. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer. 1982;49:1131–1134
  43. Newland RC, Chapuis PH, Pheils MT, MacPherson JG. The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer. 1981;47:1424–1429
  44. Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer. 1980;45:2969–2974
  45. Zinkin LD. A critical review of the classifications and staging of colorectal cancer. Dis Colon Rectum. 1983;26:37–43
  46. UICC (International Union Against Cancer). TNM classification of malignant tumours, 6th ed. Sobin LH, Wittekind Ch, editors. New York, Chichester, weinheim, Brisbane, Singapore, Toronto: Wiley-Liss. 2002.
  47. Dershaw DD, Enker WE, Cohen AM, Sigurdson ER. Transrectal ultrasonography of rectal carcinoma. Cancer. 1990;66:2336–2340
  48. Butch RJ, Stark DD, Wittenberg J, et al. Staging rectal cancer by MR and CT. AJR Am J Roentgenol. 1986;146:1155–1160
  49. Guinet C, Buy JN, Ghossain MA, et al. Comparison of magnetic resonance imaging and computed tomography in the preoperative staging of rectal cancer. Arch Surg. 1990;125:385–388
  50. Van Cutsem E, Dicato M, Wils J, et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer. 2002;38:1429–1436
  51. Compton CC. The pathology report in colorectal cancer: a user's guide. ASCO Educ. 2003;502–516
  52. Tepper JE, O’Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001;19:157–163
  53. Holscher AH. Invasive ultrasound: value of intraoperative and laparoscopic ultrasound imaging. Bildgebung. 1995;62(Suppl. 1):39–42
  54. Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer. 1986;57:1866–1870
  55. Sternberg A, Sibirsky O, Cohen D, Blumenson LE, Petrelli NJ. Validation of a new classification system for curatively resected colorectal adenocarcinoma. Cancer. 1999;86:782–792
  56. Deans GT, Parks TG, Rowlands BJ, Spence RA. Prognostic factors in colorectal cancer. Br J Surg. 1992;79:608–613
  57. Arbman G, Nilsson E, Hallbook O, Sjodahl R. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg. 1996;83:375–379
  58. Wolmark N, Wieand HS, Rockette HE, et al. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg. 1983;198:743–752
  59. Filella X, Molina R, Grau JJ, et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg. 1992;216:55–59
  60. Fitzgerald SD, Longo WE, Daniel GL, Vernava AM. Advanced colorectal neoplasia in the high-risk elderly patient: is surgical resection justified?. Dis Colon Rectum. 1993;36:161–166
  61. Stephenson KR, Steinberg SM, Hughes KS, et al. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg. 1988;208:679–687
  62. Voogt PJ, van d V, Brand A, et al. Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer. 1987;59:836–843
  63. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol. 1994;12:1859–1867
  64. Busch OR, Hop WC, Hoynck vPM , Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993;328:1372–1376
  65. Donohue JH, Williams S, Cha S, et al. Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. J Clin Oncol. 1995;13:1671–1678
  66. Kohne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308–317
  67. Sargent DJ, Kohne CH, Sanoff HK, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:1948–1955
  68. Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000;356:373–378
  69. Douillard JY, Bennouna J. Adjuvant chemotherapy for colon cancer: a confusing area!. Ann Oncol. 2005;16:1853–1854
  70. Wils J. Adjuvant treatment of colon cancer: past, present and future. J Chemother. 2007;19:115–122
  71. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol. 2004;22:1564–1571
  72. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008;26:380–385
  73. Chiara S, Nobile MT, Vincenti M, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998;42:336–340
  74. NGTATG . Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol. 1992;10:904–911
  75. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306:752–755
  76. Goldberg RM, Hatfield AK, Kahn M, et al. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol. 1997;15:3320–3329
  77. Dwight RW, Higgins GA, Keehn RJ. Factors influencing survival after resection in cancer of the colon and rectum. Am J Surg. 1969;117:512–522
  78. Grinnell RS. Results of ligation of the inferior mesenteric artery at the aorta in resections for carcinomas of the descending and sigmoid colon and rectum. Surg Gynecol Obstet. 1965;120:1031–1035
  79. O’Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246–250
  80. Haller DG, Eastern Cooperative Oncology Group. NCI High Priority Clinical Trial—Phase III Randomized Comparison of Adjuvant Low-Dose CF/5-FU vs High-Dose CF/5-FU vs Low-Dose CF/5-FU/LEV vs 5-FU/LEV Following Curative Resection in Selected Patients with Dukes’ B2 and C Carcinoma of the Colon (Summary Last Modified 06/97), EST-2288, clinical trial, closed, 07/13/1992. TRIAL 1992;0.
  81. Saini S, Cunningham D, Norman A, et al. Multicentre Randomized Trial OF Protracted Venous Infusion (PVI) 5FU compared to 5FU/folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer. Proc ASCO. 2000;19:240a
  82. Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21:2896–2903
  83. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351
  84. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116
  85. Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–2204
  86. Allegra CJ, Yothers G, O’Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27:3385–3390
  87. Wolmark N, Yothers G, O’Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009;27(18S):LBA4
  88. Cassidy J, Scheithauer W, McKendric J, et al. Capecitabine (X) versus bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (X-ACT study): positive efficacy results of a phase III trial. J Clin Oncol. 2004;22(14S):247s
  89. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–2704
  90. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol. 2007;25:102–109
  91. Wolmark N, Wieand S, Lembersky B, et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. J Clin Oncol. 2004;22(14S):
  92. Saltz L, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc ASCO. 2004;22(14S):245s
  93. Van CE, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117–3125
  94. Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol. 2000;11(Suppl. 3):29–36
  95. Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984;119:647–651
  96. Coppa GF, Eng K, Ranson JH, Gouge TH, Localio SA. Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors. Ann Surg. 1985;202:203–208
  97. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241–1246
  98. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29
  99. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990;8:1885–1893
  100. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–1047
  101. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947
  102. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–147
  103. Goldberg RM, Morton RF, Sargent DJ, et al. N9741:oxaliplatin (oxal) or CPT-11+5-fluorouracil (5FU)/leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc ASCO. 2002;21:128a
  104. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc ASCO. 2002;21:129a
  105. Kohne CH, Van Cutsem E, Wils J, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986. Proc ASCO. 2003;22:254
  106. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  107. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  108. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  109. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008;19:1829–1835
  110. Daly J, Kemeny M. Therapy of colorectal hepatic metastases. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Important advances in oncology. Philadelphia: JB Lippincott Company; 1986;p. 251–268
  111. Ridge JA, Daly JM. Treatment of colorectal hepatic metastases. Surg Gynecol Obstet. 1985;161:597–607
  112. Butler J, Attiyeh FF, Daly JM. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet. 1986;162:109–113
  113. Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986;73:727–731
  114. Wagner JS, Adson MA, van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984;199:502–508
  115. Barbare JC, Bedenne L, Bouche O, et al. What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part). Gastroenterol Clin Biol. 1999;23:486–496
  116. Hamady ZZ, Cameron IC, Wyatt J, et al. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1cm rule. Eur J Surg Oncol. 2006;32:557–563
  117. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125–7134
  118. Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261–1268
  119. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8:347–353
  120. Adam R, Pascal G, Azoulay D, et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003;238:871–883
  121. Fortner JG, Silva JS, Golbey RB, Cox EB, Maclean BJ. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg. 1984;199:306–316
  122. Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg. 1997;225:51–60
  123. Nordlinger B, Vaillant JC, Guiguet M, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol. 1994;12:1491–1496
  124. Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg. 2002;235:863–871
  125. Morise Z, Sugioka A, Fujita J, et al. Does repeated surgery improve the prognosis of colorectal liver metastases?. J Gastrointest Surg. 2006;10:6–11
  126. Alberts SR, Donohue JH, Mahoney MR, et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. Proc ASCO. 2003;22:263
  127. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663–669
  128. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  129. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933–939
  130. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–1676
  131. Quenet F, Nordlinger B, Rivoire M, et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial. Proc ASCO. 2004;22:273
  132. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–1319
  133. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008;26:5254–5260
  134. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830–1835
  135. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008;206:96–106
  136. Langer B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc ASCO. 2002;21:149a
  137. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–4982
  138. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906–4911
  139. Mocellin S, Pilati P, Lise M, Nitti D. Hepatic arterial infusion (HAI) compared to systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma: a systematic review and meta-analysis of randomized controlled trials. J Clin Oncol. 2007;25(No. 18S):626s
  140. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048
  141. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005;352:734–735
  142. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987;206:685–693
  143. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107:459–465
  144. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10:1112–1118
  145. Kemeny N, Cohen A, Seiter K, et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol. 1993;11:330–335
  146. MAGC . Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst. 1996;88:252–258
  147. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210–2218
  148. Ben Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739–8747
  149. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–1016
  150. Thomas DS, Nauta RJ, Rodgers JE, et al. Intraoperative high-dose rate interstitial irradiation of hepatic metastases from colorectal carcinoma. Results of a phase I–II trial. Cancer. 1993;71:1977–1981
  151. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23:1358–1364
  152. McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg. 2006;93:1192–1201
  153. Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2008;CD006039
  154. Girard P, Ducreux M, Baldeyrou P, et al. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol. 1996;14:2047–2053
  155. McAfee MK, Allen MS, Trastek VF, et al. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg. 1992;53:780–785
  156. Okumura S, Kondo H, Tsuboi M, et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg. 1996;112:867–874
  157. Pfannschmidt J, Muley T, Hoffmann H, Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg. 2003;126:732–739
  158. Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg. 2002;124:1007–1013
  159. Vogelsang H, Haas S, Hierholzer C, et al. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg. 2004;91:1066–1071
  160. Schmoll H, Kohne CH, Lorenz M, et al. Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU24h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): a randomized phase III study of the EORTC GITCCG and the AIO. Proc ASCO. 2000;19:241a
  161. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13:566–575
  162. Hoff PM, Royce M, Medgyesy D, Brito R, Pazdur R. Oral fluoropoyrimidines. Semin Oncol. 1999;26:640–646
  163. Saif MW. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer. 2005;5:89–100
  164. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer. 2002;38(Suppl. 2):15–20
  165. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–914
  166. Saltz LB, Douillard J, Pirrotta N, et al. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc ASCO. 2000;19:242a
  167. Kohne CH, Van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005;23:4856–4865
  168. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999;17:3560–3568
  169. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol. 1998;25:32–39
  170. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol. 1999;26:647–662
  171. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33:214–219
  172. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30
  173. Sanoff HK, Sargent DJ, Campbell ME, et al. N9741: survival update and prognostic factor analysis of oxaliplatin (Ox) and irinotecan (Iri) combinations for metastatic colorectal cancer (MCRC). J Clin Oncol. 2007;25(No. 18S):180s
  174. Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001;345:144–145
  175. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801–3807
  176. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23:4866–4875
  177. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–1214
  178. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005;23:9441–9442
  179. Seymour MT. Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC). Proc ASCO. 2005;23(No. 16S):250s
  180. Punt CJ, Koopman M, Douma J, et al. Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study. Proc ASCO. 2007;25
  181. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol. 2006;24:394–400
  182. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. Proc ASCO. 2007;25(No. 18S):166s
  183. Labianca R, Floriani I, Cortesi E, et al. Alternating versus continuous “FOLFIRI” in advanced colorectal cancer (ACC): a randomized “GISCAD” trial. Proc ASCO. 2006;24(No. 18S):147s
  184. Massuti B, Gómez A, Sastre J, et al. Randomized phase III trial of the TTD Group comparing capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continuous infusion (FUFOX) as first line treatment in advanced or metastatic colorectal cancer (CRC). Proc ASCO. 2006;24(No. 18S):165s
  185. Arkenau H, Schmoll H, Kubicka S, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis. Proc ASCO. 2005;23(No. 16S):247s
  186. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). Proc ASCO. 2007;25(No. 18S):171s
  187. Rea DW, Nortier JW, Bokkel Huinink WW, et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol. 2005;16:1123–1132
  188. Fuchs C, Marshall J, Mitchell E, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC: updated efficacy data. Proc ASCO. 2007;25(No. 18S):170s
  189. Aust D, Kohne C, Goekkurt E, et al. Preliminary pharmacogenetic evaluation of toxicity data in the prospective multicentre EORTC trial 40015 in metastatic colorectal cancer (CRC). Proc ASCO. 2006;24(No. 18S):138s
  190. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994;344:1255–1260
  191. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer. 1994;73:556–562
  192. Eng C, Maurel J, Scheithauer W, et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. Proc ASCO. 2007;25(No. 18S):164s
  193. Au H, Karapetis C, Jonker D, et al. Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial. Proc ASCO. 2007;25(No. 18S):164s
  194. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544
  195. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc ASCO. 2007;25
  196. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc ASCO. 2006;24(No. 18S):148s
  197. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208
  198. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc ASCO. 2004;22:248
  199. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330–1338
  200. Hohler T, Dittrich C, Lordick F, et al. A phaseI/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR): preliminary results. Ann Oncol. 2004;15(Suppl. 3):iii69
  201. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc ASCO. 2002;21:135a
  202. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc ASCO. 2004;22:248
  203. Van Cutsem E, Mayer RJ, Gold P, et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer. 2004;8(Suppl. 2):85–86279a
  204. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol. 2007;25(No. 18S):172s
  205. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–1664
  206. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc ASCO. 2004;22:248
  207. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc ASCO. 2007;25
  208. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634
  209. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772–4778
  210. Van Cutsem E, Tabernero J, Diaz-Rubio E, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Ann Oncol. 2004;15(Suppl. 3):iii91
  211. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803–1810
  212. Lievre A, Bachet JB, Le CD, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995
  213. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–379
  214. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765
  215. Van Cutsem E, Lang I, D’haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 2008;26(20 Suppl.):5s
  216. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol. 2008;26(No. 15S):178s
  217. Di NF, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–5712
  218. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO. 2005;23
  219. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol. 2008;26(Suppl.):180s
  220. Hecht JR, Mitchell E, Chidiac T. An updated analysis of the safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev)±panitumumab (pmab) for firstline treatment (tx) of etastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). In: Program and abstracts of the 2008 gastrointestinal cancers symposium. Orlando, FL, January 25–27. 2008;abstract 2008
  221. Taylor I. Colorectal cancer—future trends. Eur J Surg Oncol. 1995;21:351–352
  222. Martin EWJ, Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg. 1985;202:310–317
  223. Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–947
  224. Safi F, Link KH, Beger HG. Is follow-up of colorectal cancer patients worthwhile?. Dis Colon Rectum. 1993;36:636–643
  225. Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg. 1994;219:174–182

PII: S1040-8428(10)00011-9

doi: 10.1016/j.critrevonc.2010.01.010

Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 106-133 , May 2010

Article Tools

* Image Usage & Resolution